Clinical Trial Update: Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of nimotuzumab plus nab-paclitaxel for esophageal squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Zhejiang University | Conditions: Squamous Cell Carcinoma of Esophagus | Phase 2 | Status: WITHDRAWN